U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C17H22N2S.C4H6O6
Molecular Weight 436.522
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of THENALIDINE TARTRATE

SMILES

O[C@H]([C@@H](O)C(O)=O)C(O)=O.CN1CCC(CC1)N(CC2=CC=CS2)C3=CC=CC=C3

InChI

InChIKey=JNZAGODMPIMPAM-LREBCSMRSA-N
InChI=1S/C17H22N2S.C4H6O6/c1-18-11-9-16(10-12-18)19(14-17-8-5-13-20-17)15-6-3-2-4-7-15;5-1(3(7)8)2(6)4(9)10/h2-8,13,16H,9-12,14H2,1H3;1-2,5-6H,(H,7,8)(H,9,10)/t;1-,2-/m.1/s1

HIDE SMILES / InChI

Molecular Formula C17H22N2S
Molecular Weight 286.435
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C4H6O6
Molecular Weight 150.0868
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: Description was created based on several sources, including http://www.drugbank.ca/drugs/DB04826 http://www.un.org/esa/coordination/CL12.pdf

Thenalidine is an antihistamine with anticholinergic properties used as an antipruritic drug. It was withdrawn from the US, Canadian, and UK markets due to a risk of neutropenia. Thenalidine is an antagonist of the H1-receptor.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Sandostene

Approved Use

for the management of dermatologic and allergic conditions

Launch Date

1952
Doses

Doses

DosePopulationAdverse events​
25 mg 3 times / day multiple, oral (starting)
Dose: 25 mg, 3 times / day
Route: oral
Route: multiple
Dose: 25 mg, 3 times / day
Sources:
unhealthy, 41 years
n = 1
Health Status: unhealthy
Age Group: 41 years
Sex: M
Population Size: 1
Sources:
Disc. AE: Agranulocytosis...
AEs leading to
discontinuation/dose reduction:
Agranulocytosis (grade 5)
Sources:
AEs

AEs

AESignificanceDosePopulation
Agranulocytosis grade 5
Disc. AE
25 mg 3 times / day multiple, oral (starting)
Dose: 25 mg, 3 times / day
Route: oral
Route: multiple
Dose: 25 mg, 3 times / day
Sources:
unhealthy, 41 years
n = 1
Health Status: unhealthy
Age Group: 41 years
Sex: M
Population Size: 1
Sources:
PubMed

PubMed

TitleDatePubMed
Patents

Sample Use Guides

Thenalidine was given in coated tablets, each containing 25 mg. of the active ingredient. The initial dosage was 2 tablets 4 times a day until the patient improved, or for at least one week. The maintenance dose varied between 3 and 6 tablets daily, 4 tablets daily being the average. Intravenous injection of 10 ml. of thenalidine tartrate plus calcium (50 mg. of Sandostene and 1.375 g. of calcium gluconogalactogluconate) was given in a few severe and acute cases only.
Route of Administration: Other
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Fri Dec 15 17:59:11 GMT 2023
Edited
by admin
on Fri Dec 15 17:59:11 GMT 2023
Record UNII
H581Q95SJA
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
THENALIDINE TARTRATE
MART.   WHO-DD  
Common Name English
1-METHYL-4-AMINO-N-PHENYL-N-(2-THENYL)PIPERIDINE TARTRATE
Common Name English
SANDOSTEN
Brand Name English
SANDOSTENE
Brand Name English
THENALIDINE TARTRATE [MART.]
Common Name English
SANDOSTEIN
Brand Name English
THENOPHENOPIPERIDINE TARTRATE
Common Name English
Thenalidine tartrate [WHO-DD]
Common Name English
4-PIPERIDINAMINE, 1-METHYL-N-PHENYL-N-(2-THIENYLMETHYL)-, (2R,3R)-2,3-DIHYDROXYBUTANEDIOATE (1:1)
Systematic Name English
AS-716
Code English
Code System Code Type Description
CAS
16509-35-6
Created by admin on Fri Dec 15 17:59:11 GMT 2023 , Edited by admin on Fri Dec 15 17:59:11 GMT 2023
SUPERSEDED
EPA CompTox
DTXSID90937038
Created by admin on Fri Dec 15 17:59:11 GMT 2023 , Edited by admin on Fri Dec 15 17:59:11 GMT 2023
PRIMARY
EVMPD
SUB04771MIG
Created by admin on Fri Dec 15 17:59:11 GMT 2023 , Edited by admin on Fri Dec 15 17:59:11 GMT 2023
PRIMARY
PUBCHEM
27900
Created by admin on Fri Dec 15 17:59:11 GMT 2023 , Edited by admin on Fri Dec 15 17:59:11 GMT 2023
PRIMARY
FDA UNII
H581Q95SJA
Created by admin on Fri Dec 15 17:59:11 GMT 2023 , Edited by admin on Fri Dec 15 17:59:11 GMT 2023
PRIMARY
ECHA (EC/EINECS)
220-493-8
Created by admin on Fri Dec 15 17:59:11 GMT 2023 , Edited by admin on Fri Dec 15 17:59:11 GMT 2023
PRIMARY
SMS_ID
100000084801
Created by admin on Fri Dec 15 17:59:11 GMT 2023 , Edited by admin on Fri Dec 15 17:59:11 GMT 2023
PRIMARY
CAS
2784-55-6
Created by admin on Fri Dec 15 17:59:11 GMT 2023 , Edited by admin on Fri Dec 15 17:59:11 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY